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Background and purpose: Magnetic resonance guided radiotherapy (MRgRT) has been successfully implemented
for several routine clinical applications in adult patients. The purpose of this study is to map the potential benefit
of MRgRT on toxicity reduction and outcome in pediatric patients treated with curative intent for primary and
metastatic sites.
Materials and methods: Between May and August 2020, a survey was distributed among SIOPE- and COGaffiliated radiotherapy departments, treating at least 25 pediatrics patients annually and being (candidate)
users of a MRgRT system. The survey consisted of a table with 45 rows (clinical scenarios for primary (n = 28)
and metastatic (n = 17) tumors) and 7 columns (toxicity reduction, outcome improvement, PTV margin
reduction, target volume daily adaptation, online re-planning, intrafraction motion compensation and on-board
functional imaging) and the option to answer by ‘yes/no’ . Afterwards, the Dutch national radiotherapy cohort
was used to estimate the percentage of pediatric treatments that may benefit from MRgRT.
Results: The survey was completed by 12/17 (71% response rate) institutions meeting the survey inclusion
criteria. Responders indicated an ‘expected benefit’ from MRgRT for toxicity/outcome in 7% (for thoracic
lymphomas and abdominal rhabdomyosarcomas)/0% and 18% (for mediastinal lymph nodes, lymph nodes
located in the liver/splenic hilum, and liver metastases)/0% of the considered scenarios for the primary and
metastatic tumor sites, respectively, and a ‘possible benefit’ was estimated in 64%/46% and 47%/59% of the
scenarios. When translating the survey outcome into a clinical perspective a toxicity/outcome benefit, either
expected or possible, was anticipated for 55%/24% of primary sites and 62%/38% of the metastatic sites.
Conclusion: Although the benefit of MRgRT in pediatric radiation oncology is estimated to be modest, the po
tential role for reducing toxicity and improving clinical outcomes warrants further investigation. This fits best
within the context of prospective studies or registration trials.
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Table 1
Percentage of survey responders (N = 12) expecting a benefit for the five functionalities of MRgRT compared to CBCT-guided photon or proton therapy for different
areas in the body and corresponding pediatric tumor scenarios. A percentage of ≤25% (=3/12) was marked as ‘no’ benefit, a percentage between 25% and 75% was
assigned to a ‘maybe benefit’ (in italic), and ≥75% (=9/12) as ‘expected clinical benefit’ (in bold).
Brain

PTV margin
reduction

Daily adaptation of the
target volume
delineation

Online replanning for
optimal OAR sparing

Compensation for
intrafraction motion

Functional imaging
during the session

Primary RT, type diffuse midline glioma
Primary RT, type craniopharyngioma
Post-operative with tumor in situ, type posterior fossa
ependymoma
Post-operative with tumor in situ, type
craniopharyngioma
Post-operative without tumor in sity, type high-grade
glioma
Craniospinal RT, no macroscopic tumor in situ
Craniospinal RT, with metastatic laesions in situ

33%
42%
50%

0%
50%
17%

0%
42%
25%

17%
17%
17%

58%
33%
50%

42%

42%

42%

17%

33%

33%

25%

25%

17%

50%

8%
33%

0%
25%

8%
42%

25%
25%

17%
25%

50%
42%
33%
25%

33%
58%
0%
8%

50%
50%
25%
42%

17%
17%
17%
25%

58%
50%
8%
8%

67%
75%
50%
17%

67%
67%
33%
17%

67%
67%
33%
33%

67%
67%
67%
42%

50%
50%
8%
25%

17%

17%

33%

42%

17%

100%
83%

75%
50%

83%
83%

67%
58%

58%
50%

50%

17%

58%

42%

0%

17%

25%

42%

50%

42%

8%

8%

33%

33%

0%

58%
83%

67%
75%

75%
83%

33%
58%

50%
58%

17%
50%

17%
50%

42%
67%

17%
58%

17%
17%

75%

42%

33%

25%

42%

58%

25%

33%

25%

42%

33%

8%

17%

17%

8%

Head & Neck
Primary RT, type parameningeal rhabdomyosarcoma
Primary RT, type nasopharynx
Post-operative RT, type parotid gland
Post-operative RT, type neuroblastoma
Thorax
Primary RT, type mediastinal germ cell tumor
Primary RT, type lymphoma
Post-operative RT, type Ewing sarcoma arising from rib
Whole lung RT with tumor in situ, type mets from
Ewing or Wilms
Whole lung RT without tumor in situ, type Ewing or
Wilms
Abdomen
Primary RT, type rhabdomyosarcoma
Post-operative RT with tumor in situ, type
neuroblastoma
Post-operative RT without tumor in situ, type Wilms
tumor or neuroblastoma
Whole abdomen irradiation with tumor in situ, type
rhabdomyosarcoma or desmoplastic small blue
round cell tumor
Whole abdomen irradiation without tumor in situ, type
Wilms tumor
Pelvis
Primary RT, type Ewing of pelvic bones
Primary RT, type rhabdomyosarcoma of prostate/
bladder region
Post-operative RT, type Ewing of pelvic bones
Post-operative RT, type rhabdomyosarcoma of
prostate/bladder region
Extremities
Primary or pre-operative RT, type rhabdomyosarcoma
or Ewing sarcoma
Post-operative with tumor in situ, type
rhabdomyosarcoma or Ewing sarcoma
Post-operative without tumor in situ, type
rhabdomyosarcoma or Ewing sarcoma

1. Introduction

reported times for MRgRT treatment delivery, when a new plan is
generated on the daily anatomy, ranges between 40 and 50 min per
fraction [11–13]. Two thirds of the total treatment time per fraction
consists of patient set-up, MR imaging, MR registration with pretreatment imaging, daily delineation, re-planning and plan QA. Re
ductions in PTV margins and improvements in sparing OARs are
potentially achievable with MRgRT compared to a cone beam computed
tomography (CBCT) guided workflow [10,14].
Current applications for magnetic resonance guided radiotherapy
(MRgRT) are focused on adults, particularly for moving targets in the
abdomen and pelvis, while MRgRT in pediatrics is limited to two casereports [15,16]. The first addresses the treatment of a 3-year old girl
with a rhabdomyosarcoma near the diaphragm which illustrates how
the treated volume was reduced by MRgRT [15] while the second de
scribes the treatment of a 1.5-years old male with a rhabdoid tumor of

MRgRT combines magnetic resonance imaging with a radiation
therapy unit, allowing real-time MR-imaging, including functional im
aging, improved soft-tissue contrast of target volumes and organs at risk
(OARs) before, during and after treatment delivery, and online adaptive
re-planning if necessary. Re-planning is particularly useful for sites
affected by inter- and intrafraction motion.
R-IDEAL phase 0 studies, defined as radiotherapy (RT) predicate
studies [1], demonstrate that a clinical gain of MRgRT is expected by
[2–6]: (1) a reduction of the planning target volume (PTV) expansion;
(2) better sparing of the OARs; and/or the (3) possibility of online daily
functional MR imaging. Early clinical results show that MRgRT has been
successfully implemented with a re-planning and quality assurance (QA)
workflow suitable for routine clinical application [7–10]. Typically
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Table 2
Percentage of survey responders (N = 12) expecting a benefit for the five functionalities of MRgRT compared to CBCT-guided photon or proton therapy for five
metastatic tumor sites in pediatrics treated with a curative intent. A percentage of ≤25% (=3/12) was marked as ‘no benefit’, a percentage between 25% and 75% was
assigned to ‘maybe benefit’ (in italic) and ≥75% (=9/12) as ‘expected clinical benefit’ (in bold).
Brain

PTV margin
reduction

Daily adaptation of the target
volume delineation

Online replanning for
optimal OAR sparing

Compensation for
intrafraction motion

Functional imaging
during the session

Primary RT, 1–3 metastases
Primary RT, >3 metastases
Post-operative RT, (1 metastasis)

33%
17%
58%

33%
25%
42%

25%
33%
42%

17%
8%
8%

25%
17%
0%

67%
92%
92%

58%
75%
67%

58%
92%
100%

42%
75%
75%

50%
67%
42%

92%

83%

92%

83%

50%

75%

58%

83%

58%

50%

Lymph node
Head & neck region, primary RT
Mediastinum, primary RT
Upper abdomen, para-aortic
region, primary RT
Upper abdomen, liver/splenic
hilum, primary RT
Pelvic region, iliac nodes, primary
RT
Inguinal region, primary RT

67%

50%

58%

42%

42%

Lung
Primary RT, lung mets
(independent of whole lung RT)

67%

67%

67%

83%

25%

Liver
Primary RT, liver mets
(independent of whole liver RT)

100%

75%

67%

92%

50%

Bone(marrow)
Orbit
Skull base
Skull (flat bone)
Vertebra
Pelvic bone
Extremity bones, like humerus,
femur, tibia.

25%
17%
8%
33%
17%
8%

17%
0%
0%
8%
0%
0%

33%
17%
8%
25%
17%
8%

17%
8%
8%
8%
8%
8%

8%
8%
8%
8%
8%
8%

the liver illustrating the possibility of hypofractionation by the online
adaptive workflow [16].
MRgRT is a new technology on the market and as for all new tech
niques the added value has to be assessed. Whether MRgRT can enhance
the dosimetric therapeutic index in pediatrics by minimizing the treat
ment volumes through improved soft-tissue visualization, daily online
plan adaptation, real-time motion management, or daily functional MRI
hasn’t been evaluated yet. Given the differences in treatment scenarios
between adults and children the knowledge acquired for adults cannot
be directly translated to the pediatric situations. In fact, unlike adults,
the vast majority of pediatric patients with abdominal tumors like
neuroblastoma and Wilms’ tumors receives radiotherapy in the post
operative setting, where there is no gross tumor to target or visualize. In
patients with residual tumors, the availability of on-board functional
imaging (DWI, ADC) may help to individualize the treatment fractions
[17–20]. Although rarely integrated in current pediatric protocols, a
comprehensive local approach including adiotherapy to metastatic sites
in children, in line with tackling oligometastatic disease in adults, is an
interesting option for upcoming study protocols [25]. Therefore, in our
opinion assessing the added value of MRgRT is essential to understand
for which indications this technology should be introduced/used.
Moreover, literature is limited to two cases with rhabdomyosarcoma
however, for the broad spectrum of childhood tumors no data are pub
lished. Therefore, the vision of an international group of pediatric ra
diation oncologists on the potentially added value of MRgRT on toxicity
reduction and outcome improvement is important.
The purpose of this study is to estimate the potential benefit of
MRgRT for pediatric patients treated with a curative intent on primary
and metastatic lesions by sharing a survey among (candidate) users of
MRgRT systems across SIOPE and COG-affiliated radiotherapy
departments.

2. Materials and methods
2.1. International survey
Between May and August 2020, a digital survey was distributed by
email to SIOPE and COG-affiliated radiation oncologists working at
European, US, and Canadian institutions that treat at least 25 pediatrics
patients with radiotherapy per year and had purchased a MRgRT system.
Departments were identified through the ViewRay website (https://vie
wray.com/) for MRIdian and the Atlantic MR-Linac consortium member
list for Elekta Unity users [21]. Only one responder, a radiation oncol
ogist, per institution was asked to fill in and return the survey.
The questionnaire, consisting of a table with 45 rows (scenarios) and
7 columns, was designed to understand the perceived potential value of
MRgRT for pediatric tumors treated with curative intent. Primary tu
mors were assigned to six areas of the body: brain, head and neck,
thorax, abdomen, pelvis and extremities. For each area common pedi
atric radiotherapy (RT) scenarios were defined, comprising a total of 28
scenarios across these six areas (Table 1). In addition, five metastatic
tumor sites were defined: brain, lymph node, liver and lung metastases
and bone (marrow) metastases with 17 common scenarios (Table 2).
For each scenario, respondents were asked to indicate ‘yes’ or ‘no’ if
a benefit for MRgRT was expected in reducing toxicity or improving
clinical outcome when compared to a CBCT-guided photon or proton
therapy workflow. In addition, participants were asked to indicate ‘yes’
or ‘no’ for each tumor scenario if a benefit for MRgRT was expected due
to: 1) PTV margin reduction; 2) daily adaptation of the target volume
delineation; 3) online re-planning for optimal OARs sparing; 4)
compensation for intrafraction motion and 5) functional imaging during
the session.
Five additional questions addressed potential barriers of using
MRgRT in pediatric patients and one question about missing clinical
applications that had not been addressed in the survey.
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Fig. 1. Illustration of expected benefit from MRgRT for primary pediatric tumor sites. Percentage of responders (N = 12) expecting a benefit of toxicity reduction or
clinical outcome improvement by the use of MRgRT compared to a CBCT-guided photon or proton therapy for different areas in the body and common pediatric
tumor scenarios. A percentage of ≤25%, 25–75% and ≥75% were considered as ‘no’, ‘possible’, and ‘expected clinical benefit’, respectively. PrimRT = primary
radiotherapy, PostopRT = post operative radiotherapy.

3. Quantification of benefit

rhabdomyosarcomas located in the (upper) abdomen (Fig. 1). As re
ported in Table 1, the expected benefit from MRgRT for primary RT of
thoracic lymphoma was explained by PTV margin reduction, daily
adaptation of target volumes, online re-planning for optimal sparing of
OARs, intrafraction motion management, and functional imaging during
each fraction. For abdominal rhabdomyosarcoma the estimated benefits
were PTV margin reduction, online re-planning for optimal sparing of
OARs, daily adaptation of the target volumes, intrafraction motion
management, and functional imaging during each fraction.
A benefit of MRgRT on technical aspects such as PTV margin
reduction, daily target volume adaptation, online replanning, intra
fraction motion compensation was indicated for primary RT of rhab
domyosarcoma of the prostate/bladder region, post-operative RT with
tumor in situ like neuroblastoma, and primary or pre-operative RT like
rhabdomyosarcoma or Ewing sarcoma in the extremities. However, re
sponders do not expect any translation into clinical benefit for these
indications.
‘No’ benefit for reducing toxicity (with ≤25% of responders indi
cating ‘yes’) was expected in 8/28 (29%) of the considered scenarios,
mainly located in the brain. A ‘possible benefit’ was indicated by par
ticipants in 18/28 (64%) of the scenarios. These primary tumor sce
narios were mainly located in the head and neck, abdominal and pelvic
region.
None of the primary tumor scenarios scored ≥75% for expected
clinical benefit for improved clinical outcome. However, 46% (13/28) of
the scenarios were classified as a “possible benefit” such as patients with
residual masses in the thorax, abdomen, or pelvis. ‘No’ benefit was ex
pected for 54% (15/28) of the primary tumor scenarios (e.g., post
operative irradiation of neuroblastoma, and Wilms’ tumor following

Allocation of expected benefits was subdivided in three categories:
when ≤25%, 25–75%, or ≥75% of the responders answered ‘yes’, the
expected benefit for that scenario was allocated as ‘no expected benefit’,
’ possible expected benefit”, and ‘expected benefit’, respectively. With
this approach, a benefit indication was obtained for each scenario.
To put the results of the survey into a clinical perspective, an esti
mate has been made of the percentage of pediatric patients fitting the
categories of ‘yes’, ‘maybe’ and ‘no’ expected benefit using the Dutch
national cohort of pediatric cancer patients treated with curative intent
using photon therapy at UMC Utrecht and proton therapy at UMC
Groningen between January and December 2019. Pediatric Oncology in
the Netherlands is centralized at the Prinses Máxima Center (https
://www.prinsesmaximacentrum.nl/en) and radiotherapy is provided
by the two mentioned institutes. The use of the Dutch national cohort
data for the pourpose of this study has been approved by the local ethical
committee (approval number WAG/mb/20/500028).
4. Results
In total, 12 out of 17 institutions meeting the survey criteria returned
the questionnaire (71% response rate) coming from six countries, of
which three had already treated children while nine were candidate
users of MRIdian or Unity at the time of questionnaire completion,
respectively. The responders answered all questions.
For the primary tumor sites, the responders indicated an expected
benefit (≥75% answering ‘yes’) from MRgRT on toxicity reduction in 2/
28 (7%) of the scenarios considered, including thoracic lymphomas and
74
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Fig. 2. Illustration of expected benefit
from MRgRT for metastatic tumor sites
from pediatric tumors. Percentage of
responders (N = 12) expecting a benefit
of toxicity reduction or clinical outcome
improvement by the use of MRgRT
compared to a CBCT-guided photon or
proton therapy for the considered met
astatic tumor sites from pediatric can
cers. A percentage of ≤25% (=3/12)
was marked as ‘no benefit’, a percentage
between 25% and 75% was assigned to a
‘possible benefit’ and ≥75% (=9/12) as
‘expected clinical benefit’. PrimRT =
primary radiotherapy, PostopRT = post
operative radiotherapy, Pre-opRT = pre
operative radiotherapy.

gross total resection).
For the metastatic tumor sites treated with curative intent, re
sponders indicated an expected benefit (≥75% indicating ‘yes’) for
MRgRT in reducing toxicity in 3/17 (18%) scenarios. These scenarios
were mediastinal lymph nodes, lymph nodes located in the liver/splenic
hilum, and liver metastases (Fig. 2). For primary RT of lymph nodes
located in the thorax or liver/splenic hilum, a benefit from reducing
toxicity was expected because of PTV margin reduction, daily adapta
tion of target volumes, online re-planning for optimal sparing of OARs,
and intrafraction motion management (Table 2). For patients with liver
metastases, MRgRT was expected to have a benefit due to PTV margin
reduction, intra-fraction motion management, and daily adaptation of
target volumes. No benefit for toxicity reduction (≤25% indicating ‘yes’)
was expected in 6/17 considered scenarios, mainly bone metastasis,
while a ‘possible benefit’ was expected in 8/17 scenarios, including
lymph node sites in head and neck, para-aortal, pelvic and inguinal re
gion, and brain/lung metastases.
None of the responders expected a clear clinical outcome benefit for
MRgRT in all the considered metastatic scenarios. In 10/17 scenarios, a
‘possible benefit’ was expected, generally for irradiation of lymph node
sites.
Concerns about the additional burden posed by the MRgRT workflow
and the inherent features of MRgRT were indicated by a large number of
respondents. This included the possible need for additional anesthesia
(71%), the longer treatment times (63%), the fact that online recontouring may not always be feasible due to the highly-complex
target volumes (58%), and the risk of hearing damage in case of treat
ment of head and neck sites due to the fact that an headset can not be
used (42%).

Quantification of benefit was performed by modeling the application
of MRgRT in the 157 pediatric patients treated in the Netherlands with
curative intent using photons (N = 113, UMC Utrecht) and protons (N =
44, UMC Groningen) in 2019. Applying the aforementioned three
benefit categories (no, possible, yes), an expected (‘yes’) benefit for
reducing toxicity or improving clinical outcome was assigned to 6% and
0% of the primary sites, and 7% and 0% of the metastasic sites. A
possible benefit for reducing toxicity or improving clinical outcome was
estimated for 49%/24%, and 55%/38% of the primary and metastases
sites, respectively (Fig. 3).
5. Discussion
The results of this international survey, focusing on the potential
toxicity reduction and clinical outcome benefit afforded by the use of
MRgRT for pediatric patients treated with curative intent, demonstrate a
perceived marginal anticipated advantage when compared to CBCTguided photon and proton treatments in selected scenarios. A clinical
benefit was expected from toxicity reduction in patients with rhabdo
myosarcoma arising in the abdomen, lymphoma or lymph nodes in the
mediastinum, lymph nodes near the liver/splenic hilum, and liver me
tastases in ≥75% of the survey respondents.
Even if for thoracic lymphoma a clinical benefit of MRgRT is ex
pected it must be noted that MRI use in lung has lagged behind because
of inherent barriers arising from the physics of the lung itself. However,
with new MRI sequences and the application of functional imaging,
utility for this imaging technique in the thorax region is emerging
[22–23]. Nevertheless, radiotherapy for (Hodgkin or non-Hodgkin)
lymphomas is given after induction chemotherapy at a moment that
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E. Seravalli et al.

Clinical and Translational Radiation Oncology 29 (2021) 71–78

Fig. 3. Expected percentage of pediatric indications which may benefit of MRgRT, based on numbers from the Dutch national cohort (2019) and divided into primary
and metastatic tumor sites.

almost no or limited volume change is expected during the radiotherapy
course. Therefore online target volume adaptation is rarely indicated in
a setting of curative intent.
In adults, the potential disease sites that may derive clinical benefit
from MRgRT roughly correspond to the ones observed in this survey on
pediatric tumors. Winkel and colleagues reported that using MRgRT PTV
margins could be reduced and that fewer unplanned violations of highdose criteria were observed with MRgRT– compared to CBCT-based
treatments in 20 stereotactic body RT (SBRT) courses for lymph node
metastases [10]. Tetar and colleagues demonstrated that the MRgRT
workflow allowed PTV margin reduction in prostate cancer SBRT
through superior soft-tissue visualization in combination with intra
fraction motion management [12]. Also, for SBRT liver metastases,
motion management with gating has been successfully used in MRgRT
[24].
In contrast to adults, low patient numbers, complex and postoperative target volumes like Wilms’ tumors and rhabdomyosarcoma,
elongated field sizes as observed in Hodgkin lymphoma and the lack of
well-established hypofractionation regimens to treat primary or oligo
metastatic disease, hamper the easy implementation of MRgRT in the
field of pediatric oncology [25,26]. In addition, technical advances are
clearly needed in order to make MRgRT more attractive for the pediatric
patient population. For example, a larger field size and a faster volume
delineation process, perhaps through implementing deep-learning
methods, higher dose rates, and arc delivery techniques may reduce
the duration of treatment sessions and improve utilization in pediatric
patients [27–30]. Moreover, arc delivery is desired for highly conformal
dose distributions in line with intensity modulated arc techniques
available on CBCT machines.Also, the role of MR-guided functional
imaging in pediatric tumors should be further explored [31–33]. How
ever, the most important question is if this will increase at least the
perception of a potential benefit regarding toxicity reduction and
outcome improvement.
There is data on offline adaptive RT planning using MR, in contrast to

the online, daily, real-time workflow of MRgRT. Data by Merchant et al.
have demonstrated the important role of weekly MR surveillance ex
aminations in children with craniopharyngioma receiving RT to allow
for re-planning in the case of cystic change during the course of treat
ment [34]. Similarly, ad hoc offline MR may be used to inform the need
for proton re-planning in pediatric patients with intracranial or extra
cranial tumors [35]. However, cystic changes occurring in between MRI
examinations can be missed for a number of fractions, hence the po
tential benefit of daily MR imaging. In addition, several departments
might not have easy access to MRI imaging making logistics for weekly
imaging difficult.
One of the possible burdens of pediatric MRgRT is the additonal need
for anesthesia due to daily patient positioning in a narrow bore and
longer treatment fractions when compared to a CBCT-workflow.
Although longer sessions may also occur with proton therapy, the
long-term effects of daily anesthesia on children have yet to be fully
established, since concern for adverse late effects involving cognitive
function, language, emotional reactivity, and anxiety has raised in
recent publications [36–38]. In addition, anesthesia significantly in
creases treatment and financial burden [39]. Another challenge is the
patient’s inaccessibility to the anesthesiologist following placement in
the MR Linac scanner in the case of airway problems [40]. The presence
of a magnetic field also necessitates use of MR and radiotherapycompatible anesthesia equipment, with particular attention to infusion
pumps and inhalational anesthetic equipment [41].
Possible hazards from the static magnetic field exposure that could
follow the treatment on a MRgRT platform do not differ from the ones
that could arise from any other MR simulation (http://www.mrisafety.
com/). Patients with reprogrammable ventriculo-peritoneal shunts
may comprise a subset of patients that will have significant barriers to
use MRgRT. In addition, acoustic noise is a well-known cause of
discomfort during MRI. When hearing protection devices such as ear
plugs/earmuffs/headphones are not properly used, the subject is at risk
of permanent hearing damage. In principle, these devices should provide
76
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sufficient protection if correctly worn [42]. However, this is not always
the case for patients with small ear canals, neonates, and patients in
immobilization masks undergoing MR-guided RT. In particular, MRgRT
patients repetitively exposed to MRI are at risk of reaching critical levels
of cumulative noise doses, especially during a long course of fraction
ated MRgRT [43,44].
One potential limitation of this survey is that the results relied on the
knowledge of twelve respondents, of which the majority are candidate
users of MRgRT, who might have limited experience with MRgRT.
However, we posit that the participating radiation oncologists are all
experienced with pediatric RT, believe in MRgRT and therefore are best
qualified to evaluate the potential role of MRgRT in pediatrics. Another
limitation is the limited clinical experience of the responders with
MRgRT for children so the results of the survey are not really based on
practice. However, the conclusions are based on the best of knowledge
available at the moment of writing on this topic. A response rate of 71%
is comparable to response rates in other publications based on survey
results like e.g. Huijskens [25]. Therefore, it is considered sufficient to
roughly estimate the added value of MRgRT for pediatrics. The quanti
fication of the percentage of patients that may benefit from MRgRT is
based on a population-based dataset, more particularly the Dutch na
tional cohort of children treated at the UMC Utrecht and UMC Gronin
gen within or following SIOPE- and COG-protocols in 2019,. Therefore,
it is expected that the number of cases per tumor scenario mentioned is
also representative for other countries/institutes.
Given the limited annual number of candidate cases for MRgRT, it is
of utmost importance to share experiences among users in order to
bridge the gap of knowledge on the application of MRgRT in pediatric
oncology. A consortium-based collaboration will be necessary to vali
date the clinical benefits of this new technology.

[4] Vestergaard A, Hafeez S, Muren LP, Nill S, Høyer M, Hansen VN, et al. The
potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary
bladder cancer. Radiother Oncol 2016;118(1):154–9. https://doi.org/10.1016/j.
radonc.2015.11.003.
[5] Winkel D, Kroon PS, Werensteijn-Honingh AM, Bol GH, Raaymakers BW,
Jürgenliemk-Schulz IM. Simulated dosimetric impact of online replanning for
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6. Conclusions
At present, the published scope of MRgRT in pediatric patients is
limited to two case reports. Compared to CBCT-guided photon or proton
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marked as ‘interesting to explore’. Therefore, we conclude that there is a
need to perform clinical studies investigating the potential benefits of
MRgRT in pediatric oncology. To accelerate this process, an interna
tional consortium of investigators evaluating MRgRT in pediatrics will
be established.
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